BioNTech successfully closed the acquisition of CureVac.
With this, CureVac is now part of the BioNTech Group (Nasdaq: BNTX), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Please visit www.biontech.com career.curevac.com